Abstract 291P
Background
Malnutrition is one of the most frequent disorders in cancer patients which accounts for 50-90%. This high prevalence of malnutrition is very concerning as it is associated with reduced treatment efficacy, functional status, quality of life and survival. The prevalence of malnutrition varies with tumor type, site and the stage of the disease. The highest prevalence of cancer patients with nutritional deficits is seen in those with tumors of the gastrointestinal tract and lung.
Methods
It is a hospital based cross sectional study among 95 cancer patients. They were screened using Patient Generated Subjective Global Assessment (PGSGA) for malnutrition. Median and IQR were used to describe the continuous data and frequency and percentage for the categorical variables. To identify the correlation between continuous variables, Pearson’s correlation coefficient was used. At 95% confidence interval, p value less than 0.05 was termed as statistically significant. The data were analyzed using SPSS 20.0 software.
Results
Among 95 patients, 36.85% of patients were GI cancers followed by 27.37% lung cancer, breast cancer (10.53%) and rectal cancer (10.53%). Most of the patients (81.05%) were well nourished Subjective Global Assessment (SGA-A), 13.68% patients were moderately malnourished or had suspected malnutrition (SGA-B) and 5.26% patients were severely malnourished (SGA-C). There was statistically significant difference in association of malnutrition with gastrointestinal cancer. Among equally distributed limited and metastatic cancers, there was no significant association between stages of cancer with malnutrition.
Conclusions
Nutritional assessment and support should be an integral part of care in gastrointestinal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
314P - Let’s bring back old drugs to conquer resistance to KRAS G12C inhibitors in NSCLC
Presenter: Anisha Jain
Session: Poster viewing 04
315P - Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A single-center experience
Presenter: Luka Brcic
Session: Poster viewing 04
316P - Phase II study of ramucirumab and docetaxel for platinum-resistance NSCLC patients with malignant pleural effusion: Analysis of pleural effusion control rate
Presenter: Ryosuke Ogata
Session: Poster viewing 04
317P - A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer: WJOG15421 L (REVEAL)
Presenter: Taichi Matsubara
Session: Poster viewing 04